Prevalence and Prognostic Role of Resistant Hypertension in Chronic Kidney Disease Patients

被引:127
|
作者
De Nicola, Luca [1 ]
Gabbai, Francis B. [2 ,3 ]
Agarwal, Rajiv [4 ,5 ]
Chiodini, Paolo [6 ]
Borrelli, Silvio [1 ]
Bellizzi, Vincenzo [7 ]
Nappi, Felice [8 ]
Conte, Giuseppe [1 ]
Minutolo, Roberto [1 ]
机构
[1] Univ Naples 2, Dept Nephrol, I-80125 Naples, Italy
[2] Vet Adm San Diego Healthcare Syst, Dept Med, San Diego, CA USA
[3] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[4] Indiana Univ Sch Med, Dept Med, Div Nephrol, Indianapolis, IN 46202 USA
[5] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA
[6] Univ Naples 2, I-80125 Naples, Italy
[7] Salerno Hosp, Dept Nephrol, Salerno, Italy
[8] Nola Hosp, Dept Nephrol, Nola, Italy
基金
美国国家卫生研究院;
关键词
ambulatory blood pressure monitoring; chronic kidney disease; resistant hypertension; BLOOD-PRESSURE CONTROL; EUROPEAN-SOCIETY; PROTEINURIA; DYSFUNCTION; COMMITTEE; PEOPLE; TARGET;
D O I
10.1016/j.jacc.2012.12.061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study sought to evaluate in chronic kidney disease (CKD) prevalence and prognosis of true resistant hypertension (RH) (i.e., confirmed by ambulatory blood pressure [ABP] monitoring). Background In CKD, uncontrolled hypertension is a major risk factor, but no study has properly investigated the role of RH. Methods We prospectively studied 436 hypertensive CKD patients under nephrology care. Four groups were constituted by combining 24-h ABP with diagnosis of RH (office blood pressure >= 130/80 mm Hg, despite adherence to >= 3 full-dose antihypertensive drugs including a diuretic agent or >= 4 drugs): control (ABP <125/75 mm Hg without RH); pseudoresistance (ABP <125/75 mm Hg with RH); sustained hypertension (ABP >= 125/75 mm Hg without RH); and true resistance (ABP >= 125/75 mm Hg with RH). Endpoints of survival analysis were renal (end-stage renal disease or death) and cardiovascular events (fatal and nonfatal cardiovascular event). Results Age was 65 +/- 14 years, men 58%, diabetes 36%, cardiovascular disease 30%, median proteinuria 0.24 (interquartile range 0.09 to 0.83) g/day, estimated glomerular filtration rate 43 +/- 20 ml/min/1.73 m(2), office blood pressure 146 +/- 19/82 +/- 12 mm Hg, and 24-h ABP 129 +/- 17/72 +/- 10 mm Hg. True resistant patients were 22.9%, and pseudoresistant patients were 7.1%, whereas patients with sustained hypertension were 42.9%, and control subjects were 27.1%. Over 57 months of follow-up, 109 cardiovascular events and 165 renal events occurred. Cardiovascular risk (hazard ratio [95% confidence interval]) was 1.24 (0.55 to 2.78) in pseudoresistance, 1.11 (0.67 to 1.84) in sustained hypertension, and 1.98 (1.14 to 3.43) in true resistance, compared with control subjects. Corresponding hazards for renal events were 1.18 (0.45 to 3.13), 2.14 (1.35 to 3.40), and 2.66 (1.62 to 4.37). Conclusions In CKD, pseudoresistance is not associated with an increased cardio-renal risk, and sustained hypertension predicts only renal outcome. True resistance is prevalent and identifies patients carrying the highest cardiovascular risk. (C) 2013 by the American College of Cardiology Foundation
引用
收藏
页码:2461 / 2467
页数:7
相关论文
共 50 条
  • [31] The Probability of Resistant Hypertension During Dental Treatment of Chronic Kidney Disease Patients
    Chidambaram, Ramasamy
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2017, 27 (01): : 44 - 46
  • [32] Hypertension in patients with chronic kidney disease
    Chanda, Ranjan
    Fenves, Andrew Z.
    CURRENT HYPERTENSION REPORTS, 2009, 11 (05) : 329 - 336
  • [33] Hypertension in patients with chronic kidney disease
    Ranjan Chanda
    Andrew Z. Fenves
    Current Hypertension Reports, 2009, 11 : 329 - 336
  • [34] Risk Stratification of Resistant Hypertension in Chronic Kidney Disease
    Weinrauch, Larry A.
    Desai, Akshay S.
    Skali, Hicham
    D'Elia, John A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (24) : 2468 - 2470
  • [35] The double challenge of resistant hypertension and chronic kidney disease
    Rossignol, Patrick
    Massy, Ziad A.
    Azizi, Michel
    Bakris, George
    Ritz, Eberhard
    Covic, Adrian
    Goldsmith, David
    Heine, Gunnar H.
    Jager, Kitty J.
    Kanbay, Mehmet
    Mallamaci, Francesca
    Ortiz, Alberto
    Vanholder, Raymond
    Wiecek, Andrzej
    Zoccali, Carmine
    London, Gerard Michel
    Stengel, Benedicte
    Fouque, Denis
    LANCET, 2015, 386 (10003): : 1588 - 1598
  • [36] Treatment of Resistant Hypertension in the Patient With Chronic Kidney Disease
    Scher, Harry E.
    Drew, Michelle L.
    Cottrell, Damon B.
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2015, 11 (06): : 597 - 606
  • [37] Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison
    Wolley, Martin J.
    Stowasser, Michael
    CURRENT HYPERTENSION REPORTS, 2016, 18 (05)
  • [38] Endothelin antagonists and resistant hypertension in chronic kidney disease
    Moore, Rebecca
    Linas, Stuart
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2010, 19 (05): : 432 - 436
  • [39] Resistant hypertension and chronic kidney disease: Epidemiology and prognosis
    Seidowsky, Alexandre
    Massy, Ziad A.
    Metzger, Marie
    Stengel, Benedicte
    NEPHROLOGIE & THERAPEUTIQUE, 2014, 10 (03): : 137 - 144
  • [40] Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison
    Martin J Wolley
    Michael Stowasser
    Current Hypertension Reports, 2016, 18